News

Pharmaceutical, biotech and academic laboratories long have tried to develop drugs to target Ras. Most of the efforts focused on K-Ras, which is one of the three different types, or “isoforms,” of Ras – the others are N-Ras and H-Ras – and is the most “About 85 percent of Ras mutations involve K-Ras

When Todd and Lisa Harris were informed that their 10-month-old son Evan had cancer, they were very upset, but they also felt as if a weight had been lifted. “At least now we had an answer, albeit an extremely painful one, and a path forward,” Lisa Harris said about her son’s diagnosis at the time

A research team led by UC San Francisco scientists has shown that cancer-induced structural changes in a sugary coating ensheathing cells can promote mechanical interactions that fuel tumor growth and metastasis. Every introductory biology class teaches that cells are enclosed by a membrane, but it

It’s one of the most common and deadly drivers of cancer, yet it has eluded any drug therapies for decades. Now, buoyed by recent research breakthroughs and funding support, scientists are pushing harder than ever to target what has been called "undruggable." In the epic fight against cancer, a

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain

Research led by a UC San Francisco investigator establishes a new benchmark in the treatment of patients with metastatic colorectal cancer and sets a new expectation for how long patients can live with the particularly lethal disease. The research, which spanned a decade, was unveiled at a plenary

From prostate cancer to immunotherapy to genetic testing, UC San Francisco research is providing new insights and aiding in the development of new treatment strategies for cancer. Some of the latest research will be unveiled at the annual meeting of the American Society of Clinical Oncology (ASCO)